The global Next-Generation Sequencing (NGS) market is expected to grow at a compound annual growth rate of 13.54% from USD 13.70 billion in 2026 to USD 43.18 billion in 2035.
.webp)
Global Next-generation sequencing Market Revenue and Trends
The next-generation sequencing market consists of high-throughput, accurate analysis of DNA and RNA sequences using the latest genomic sequencing technologies, instrumentation, consumables and software, and bioinformatics tools. This comprises sequencing platforms and instrumentation, sample preparation kits, reagents for sequencing, flow cells, target enrichment and analysis tools, software designed for analysis of sequence data, cloud-based bioinformatics platforms, and sequencing services.
The applications for next-generation sequencing technologies include a wide variety of applications such as clinical diagnostics, oncology, infectious diseases, reproductive genetics, rare diseases, precision medicine, drug discovery, agriculture genetics, and research.
Next-generation sequencing has helped researchers to gain a holistic genetic view of individual patients by reducing turnaround times for sequencing and lowering overall sequencing costs, and is a key technology of modern genomic medicine and life science research. Next-generation sequencing market growth is primarily being driven by the rise of precision medicine, increasing rates of cancer and genetic diseases, increased investment in genomic research, and rapid developments and technological improvements in the platforms that perform high-throughput sequencing of DNA and RNA molecules. Growth is also being driven by increased integration and use of clinical applications, government support, funding for genomic initiatives, and implementation of artificial intelligence (AI) and advanced bioinformatics in genomic data analysis.
What are the key drivers for the global Next-generation sequencing market?
Global Next-generation Sequencing (NGS) market is experiencing substantial growth driven by the rising need to analyze genomes at high speeds and an affordable and accurate pace in the healthcare and life science industries. Healthcare providers, research institutions and pharmaceutical companies are greatly adopting these NGS technologies for diagnoses of diseases, discovery of biomarkers, companion diagnosis and personalized therapies.
The mounting challenges of cancers, rare genetic diseases, infectious diseases and hereditary diseases are largely fueling the increasing demand for comprehensive genomic sequencing solutions which can facilitate precision medicine and the early discovery of the diseases.
Advancements in sequencing chemistry, automation, long-read sequencing, single-cell genomics and cloud based bioinformatics are shaping the future for the NGS by increasing the speed, accuracy and scalability of sequencing and ease of its analysis. Manufacturers are offering low-cost and faster sequencing platforms, artificial intelligence (AI) enabled genomic analysis tools and integrated workflows to simplify the laboratory workflow.
In addition, increase in government driven genomics programs, significant funding for biomarker-based drug development in the pharmaceutical industry and rising usage of genomic testing in the clinics are expected to provide ample of long-term opportunities to the global NGS market.
Opportunities Impact Analysis
Impact Factor | Estimated CAGR Impact | Regional Relevance | Market Impact |
Expanding adoption of precision medicine and personalized healthcare | +3.6% | North America, Europe, Asia Pacific | Increases demand for next-generation sequencing in genomic profiling, targeted therapy selection, and individualized disease management across clinical settings. |
Growing investments in cancer genomics and companion diagnostics | +3.2% | North America, Europe | Accelerates the use of NGS for biomarker discovery, tumor characterization, treatment monitoring, and precision oncology applications. |
Rising government funding for national genomics and population sequencing programs | +2.8% | Asia Pacific, Europe, North America | Supports large-scale genomic research, rare disease diagnosis, public health initiatives, and expansion of sequencing infrastructure. |
Increasing pharmaceutical and biotechnology adoption in drug discovery and clinical research | +2.3% | Global | Creates opportunities for NGS in biomarker identification, clinical trial stratification, pharmacogenomics, and novel therapeutic development. |
Advancements in sequencing platforms, automation, and AI-driven bioinformatics | +1.9% | Global | Enhances sequencing speed, improves analytical accuracy, reduces turnaround time, and simplifies genomic data interpretation for research and clinical laboratories. |
Challenges Impact Analysis
Impact Factor | Estimated CAGR Impact | Regional Relevance | Market Impact |
High capital investment for sequencing instruments and laboratory infrastructure | -2.5% | Global | Limits technology adoption among smaller hospitals, diagnostic laboratories, and research institutions due to significant upfront investment requirements. |
Complex genomic data analysis and shortage of skilled bioinformatics professionals | -2.1% | North America, Europe, Asia Pacific | Creates challenges in interpreting large genomic datasets and slows the integration of sequencing results into routine clinical practice. |
Regulatory and ethical concerns related to genomic testing and patient data | -1.8% | North America, Europe | Increases compliance requirements for clinical validation, genetic data privacy, and regulatory approvals for sequencing-based diagnostic applications. |
Reimbursement limitations for advanced genomic testing | -1.5% | Asia Pacific, Latin America | Restricts patient access to next-generation sequencing and slows adoption in routine clinical diagnostics due to inconsistent healthcare coverage. |
Data storage, cybersecurity, and interoperability challenges | -1.3% | Global | Complicates secure management, sharing, and integration of large-scale genomic datasets across healthcare systems, research organizations, and sequencing laboratories. |
Segment Insight
By Product - Consumables Largest segment in 2025 due to the consistent need for consumables such as sequencing reagents, library preparation kits, sample preparation kits, flow cells, chips, and cartridges, among others, used in each sequencing workflow. Continued growth in genomic research, clinical diagnostics, cancer testing, and large-scale sequencing initiatives, along with the consistent development of reagent chemistry and pre-designed kits suitable for automation-supported workflows, strengthens the segment’s dominance.
By Technology - Sequencing by Synthesis (SBS) Largest segment in 2025 attributed to high accuracy sequencing, scalability, cost-effectiveness, and extensive usage for various genome sequencing methods including full-genome sequencing, exome sequencing, target sequencing, whole RNA sequencing, and diagnostics for targeted therapies. These features ensure reliable performance and the use of high-throughput SBS with fully automated sequencing.
By Application - Oncology Largest segment in 2025 driven by widespread adoption of next-generation sequencing for diagnosis, genomic identification, biomarker discovery, companion diagnostics, treatment choices, and personalized medicine for cancer treatment. In light of increase in the global cancer burden, growing applications of target therapies, expanding utility of liquid biopsy for non-invasive assessment of the cancer, and significant developments of targeted therapies, cancer will lead over the forecast period.
Regional Insights
North America largest region in 2025 driven by extensive research and development activities in genomics, significant penetration of personalized medicine practices, strong support from various federal and state funding programs, and presence of major Sequencing technology providers and pharmaceutical industries in the region. With additional investments in clinical genetics, and cancer studies, with AI-led genomic bioinformatic and analyses the segment is anticipated to lead the overall market share.
Asia Pacific Fastest growing segment region in 2025 on account of growing health investments, rising genome sequencing research initiatives, increasing cancer and rarest genetic disease prevalence, and penetration of precision treatments in China, India, Japan, Australia, Singapore and South Korea. Growth of government initiatives focusing on enabling cost effective whole genome sequencing and support in developing comprehensive healthcare ecosystem by enhanced infrastructure, are anticipated to fuel market across the region.
Report Scope
Feature of the Report | Details |
Market Size in 2026 | USD 13.70 billion |
Projected Market Size in 2035 | USD 43.18 billion |
Market Size in 2025 | USD 12.13 billion |
CAGR Growth Rate | 13.54% CAGR |
Base Year | 2025 |
Forecast Period | 2026-2035 |
Key Segment | By Product, Technology, Application and Region |
Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Recent Developments
June 26 2026 San Diego, CA Illumina, Inc., leader in the genomics space, yesterday launched a quartet of first-ever, purpose built, next gen Sequencing Software and Methods to use the new field of Artificial Intelligence to get us closer to 3 day result, highly accurate sequencing and to enable the creation of multiple large scale clinical and population sequencing programs.
List of the prominent players in the Next-generation Sequencing Market:
Illumina Inc.
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd
QIAGEN N.V.
Pacific Biosciences of California Inc.
Oxford Nanopore Technologies plc
BGI Genomics Co. Ltd.
Agilent Technologies Inc.
Revvity Inc. (PerkinElmer)
Danaher Corporation
Standard BioTools Inc. (formerly Fluidigm Corporation)
Eurofins Scientific SE
Bio-Rad Laboratories Inc.
Hamilton Company
Azenta Life Sciences
10x Genomics Inc.
Integrated DNA Technologies (IDT)
MGI Tech Co. Ltd.
GENEWIZ (Azenta Life Sciences)
Novogene Co. Ltd.
Others
The Next-generation Sequencing Market is segmented as follows:
By Product
Sequencing Instruments
Consumables
Services
By Technology
Sequencing by Synthesis (SBS)
Ion Semiconductor Sequencing
Single-Molecule Real-Time (SMRT) Sequencing
Nanopore Sequencing
Other
By Application
Oncology
Clinical Diagnostics
Reproductive Health
Infectious Disease Detection
Rare & Inherited Disease Research
Drug Discovery & Development
Agrigenomics & Animal Research
Others
Regional Coverage:
North America
U.S.
Canada
Mexico
Rest of North America
Europe
Germany
France
U.K.
Russia
Italy
Spain
Netherlands
Rest of Europe
Asia Pacific
China
Japan
India
New Zealand
Australia
South Korea
Taiwan
Rest of Asia Pacific
The Middle East & Africa
Saudi Arabia
UAE
Egypt
Kuwait
South Africa
Rest of the Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
